Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry

• Published in: Annals of the rheumatic diseases Vol. 80; no. 1; pp. 134 - 136
• Main Authors: Winthrop, Kevin L, Citera, Gustavo, Gold, David, Henrohn, Dan, Connell, Carol A, Shapiro, Andrea B, Shi, Harry, Onofrei, Alina M, Pappas, Dimitrios A, Schulze-Koops, Hendrik
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and European League Against Rheumatism 01.01.2021; Elsevier Limited; BMJ Publishing Group
• Subjects: adalimumab; Adalimumab - therapeutic use; Age; Age Factors; Age groups; Aged; antirheumatic agents; Antirheumatic Agents - therapeutic use; arthritis; Arthritis, Rheumatoid - drug therapy; Biological Products - therapeutic use; biological therapy; Cardiovascular diseases; Clinical trials; Consent; Data dictionaries; Datasets; Etanercept; Female; Humans; Incidence; Infections; Infections - epidemiology; Information sharing; Janus Kinase Inhibitors - therapeutic use; Letter; Male; Medical equipment; Middle Aged; Monoclonal antibodies; Patients; Piperidines - therapeutic use; Proportional Hazards Models; Pyrimidines - therapeutic use; Registries; rheumatoid; Rheumatoid arthritis; Risk Factors; Safety; Tumor necrosis factor; tumor necrosis factor inhibitors; Tumors; United States - epidemiology; United States; New York; United States > US; arthritis; tumor necrosis factor inhibitors; antirheumatic agents; biological therapy; adalimumab; rheumatoid